Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer.

Hensing TA, Hanna NH, Gillenwater HH, Gabriella Camboni M, Allievi C, Socinski MA. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs. 2006 Jul; 17(6):697-704.

View in: PubMed

collapse authors with profiles